Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 9, 2026
Spruce Biosciences, Inc. (SPRB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$22.3 million. As of Jun 30, 2026 it held $96.3 million in cash and investments and $20.2 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-16.23M
-685.1% vs year-ago quarter
Operating cash flow
$-22.12M
-150.6% vs year-ago quarter
Free cash flow
$-22.25M
-154.6% vs prior quarter
EPS
$-6.68
-90.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.87M
+410.4% vs year-ago quarter
Net cash
$76.11M
Q2 FY2026
Operating margin
-3453.9%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1683553
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$16.5M | -$12.0M | -$11.1M | -$8.2M | -$2.7M |
| Net income | -$16.2M | -$12.3M | -$14.6M | -$8.2M | -$2.1M |
| Diluted EPS | -$6.68 | -$8.94 | -$11.35 | -$14.58 | -$3.50 |
| Operating cash flow | -$22.1M | -$8.7M | -$6.5M | -$5.3M | -$8.8M |
| Free cash flow | -$22.3M | -$8.7M | — | — | — |
| Total assets | $102.9M | $56.2M | $53.0M | $15.3M | $21.8M |
| Total liabilities | $19.1M | $21.5M | $10.5M | $9.9M | $8.6M |
| Stockholders' equity | $83.7M | $34.6M | $42.5M | $5.4M | $13.2M |
| Cash and investments | $96.3M | $54.1M | $48.9M | $10.7M | $16.4M |
| Total debt | $20.2M | $20.7M | $736,000 | $1.0M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 366 Spruce Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.